Haemonetics has acquired Vivasure, an Ireland-based company developing next-generation technology for percutaneous vessel closure, in a deal worth up to €185m ($215m) upon completion of certain milestones.
Vivasure’s PerQseal Elite system utilises a proprietary bioabsorbable patch to seal large-bore arteriotomies and venotomies up to 26 F from inside the vessel. The system offers a sutureless and fully absorbable solution, designed for structural heart and endovascular procedures.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Last year, Vivasure submitted a premarket approval (PMA) application to the US Food and Drug Administration (FDA) for the PerQseal Elite arterial closure system and received CE mark approval in Europe for both arterial and venous indications.
The ELITE arterial study, a multi-centre, single-arm, prospective trial, demonstrated ease of use for PerQseal Elite with no need for pre-close. The study reported 0% major complications at the thirty-day follow-up, along with an immediate median time to haemostasis.
The deal involves an upfront cash payment of €100m ($116.7m), with the net amount totalling approximately €52m after deducting Haemonetics’ earlier investments and loans to Vivasure, along with customary closing adjustments.
Additionally, up to €85m may be paid as contingent consideration, dependent on future sales growth and the attainment of specific milestones. Haemonetics financed the acquisition using available cash on hand.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHaemonetics interventional technologies vice-president and general manager Ken Crowley said: “Acquiring Vivasure expands Haemonetics’ complete range of closure devices with new and clinically differentiated technology to bolster our presence in the large-bore closure market and our impact in fast-growing structural heart and endovascular procedures.
“With strong clinical performance and safety data, PerQseal Elite positions us for increased leadership in advanced closure, as we leverage our commercial scale and operational synergies to deliver increased value to physicians and hospitals.”
Vivasure CEO Andrew Glass said: “We’re extremely proud of the progress made in advancing closure technology, and grateful to the clinicians, employees, board members, investors and government bodies who supported Vivasure’s mission.
“Joining Haemonetics provides the global scale and resources to accelerate the availability of PerQseal Elite and bring its clinical benefits to more physicians and patients worldwide.”
